JMP Securities Upgrades Enanta Pharmaceuticals (ENTA) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Barclays Downgrades Enanta Pharmaceuticals (ENTA) to Underweight
October 23, 2015 7:00 AM EDTBarclays downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Equalweight to Underweight with a price target of $16.00 (from $45.00).
For an analyst ratings summary and ratings history on Enanta Pharmaceuticals click here. For more ratings news on Enanta Pharmaceuticals click here.
Shares of Enanta Pharmaceuticals closed at $23.90 yesterday.
... MoreEnanta Pharma (ENTA) Halted on Second LUDP
October 22, 2015 3:30 PM EDTEnanta Pharma (NASDAQ: ENTA) Halted on Second LUDP
... MoreEnanta Pharma (ENTA) Drops Over 50%
October 22, 2015 3:29 PM EDTEnanta Pharma (NASDAQ: ENTA) shares dropped over 50% after the FDA warned of serious liver injury risk with Viekira Pak.
... MoreEnanta Pharma (ENTA) triggers limit-up, limit-down trading pause
October 22, 2015 3:14 PM EDTEnanta Pharma (NASDAQ: ENTA) triggers limit-up, limit-down trading pause. The activity is related to Abbvie news.
... More